title: Intracameral bevacizumab for iris rubeosis.
abstract: OBJECTIVE
  To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma.
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography.
  
  
  RESULTS
  Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks.
  
  
  CONCLUSIONS
  Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.
authors.affiliation: Department of Ophthalmology I, Eberhard-Karls University of Tuebingen, Tuebingen, Germany. salvatore.grisanti@med.uni-tuebingen.de
authors.forename: Salvatore
authors.initials: S
authors.lastname: Grisanti
authors.forename: Sabine
authors.initials: S
authors.lastname: Biester
authors.forename: Swaantje
authors.initials: S
authors.lastname: Peters
authors.forename: Olcay
authors.initials: O
authors.lastname: Tatar
authors.forename: Focke
authors.initials: F
authors.lastname: Ziemssen
authors.forename: Karl Ulrich
authors.initials: KU
authors.lastname: Bartz-Schmidt
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000867:Anterior Chamber / Q000187:drug effects*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002199:Capillary Permeability / Q000187:drug effects; D003930:Diabetic Retinopathy / Q000150:complications; D005260:Female; D005451:Fluorescein Angiography; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D007498:Iris / Q000098:blood supply*; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D010865:Pilot Projects; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000150:complications; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab